
EPKINLY delivered an ORR of 82%, with 60% of patients
achieving a deep response of CR1
Rapid response1
- In responders (n=104), the median time to first response was 1.4 months (range: 1-3 months)†
In a prespecified analysis of complete responders (n=76), the median time to complete response was 1.5 months (range: 1.2-11.1).2
*Efficacy results determined by Lugano criteria (2014) as assessed by Independent Review Committee (IRC).1
†Median study follow-up was 17.4 months.3
The efficacy results of the 86 patients who received the recommended 3-step up dosage schedule in the EPCORE® NHL-1 dose optimization cohort were comparable to the primary efficacy population.1‡
- Investigator-assessed efficacy outcomes3,4:
- ORR: 86% (n=74/86; 95% CI, 76.9-92.6)
- CR: 64% (n=55/86; 95% CI, 52.9-74.0)
- PR: 22% (n=19/86)
‡Median study follow-up for the dose optimization cohort was 5.7 months.3
Responses demonstrated in select refractory subgroups1,2
![Response in prespecified subgroups. Double Refractory: yes (75% ORR [n=67/89; 95% CI, 65-84], 55% CR [n=49], and 20% PR [n=18]) and no (97% ORR [n=37/38; 95% CI, 86-100], 71% CR [n=27], and 26% PR [n=10]). Refractory to last therapy responses: yes (74% ORR [n=65/88; 95% CI, 63-83], 49% CR [n=43], and 25% PR [n=22]) and no (100% ORR [n=39/39]; 95% CI, 91-100), 85% CR [n=33], and 15% PR [n=6]).](/content/dam/epcoritamabhcp/images/clinical-trial-results/responses-in-relapsed-refactory-subgroups-desktop.png)
Data Limitation: Study was not powered to evaluate these prespecified subgroups. Data are exploratory and descriptive in nature. No formal inferences can be drawn.
- Double refractory: Patients were refractory to both anti-CD20 and an alkylating agent
- Refractory: Patient with no response or relapse within 6 months after therapy
EPKINLY delivered durable responses with mDOR not reached1,2§||

![68% DOR (estimated; 95% CI, 57.6-77.0). Duration of response in overall responders and complete responders plotted against probability of response: 12 months (84% DOCR [estimated; 95% CI, 72.3-91.4]).](/content/dam/epcoritamabhcp/images/clinical-trial-results/clinical-results/overall-response-mdor-and-mdocr-over-months-desktop.png)
§Efficacy results determined by Lugano criteria (2014) as assessed by Independent Review Committee (IRC).
||Based on Kaplan-Meier estimate.
¶Both lower and upper limits of the range indicate a censored value.
CI=confidence interval; CR=complete response; DOCR=duration of complete response; DOR=duration of response; FLIPI=Follicular Lymphoma International Prognostic Index; mDOCR=median duration of complete response; mDOR=median duration of response; NHL=non-Hodgkin lymphoma; NR=not reached; ORR=overall response rate; PR=partial response.